Viatris scores a win in long-running EpiPen antitrust lawsuit, but patent settlement charge heads to trial

Generic giant Mylan has faced a slew of lawsuits targeting its EpiPen marketing strategies. Now known as Viatris, the drugmaker says it's scored a win against serious charges in an antitrust case that's been running for several years.

Viatris, the newly-formed company that combined Mylan and Pfizer's Upjohn unit late last year, said it's "pleased" with the Kansas District Court's decision to rule in favor of the company's summary judgment motion in the case, according to a Wednesday statement. Most of the charges in the case have been dismissed, but one will head to trial.